10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)

10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT00885612

Enrollment

1114

Registered

2009-04-22

Start date

2009-05-31

Completion date

2010-03-31

Last updated

2010-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

CHD-Risk, Breast Cancer, Aromatase Inhibitors, postmenopausal early breast cancer

Brief summary

10-year CHD risk evaluation and its treatment pattern analysis in postmenopausal early breast cancer patients taking aromatase inhibitors.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Time perspective

CROSS_SECTIONAL

Eligibility

Sex/Gender

FEMALE

Age

50 Years to No maximum

Healthy volunteers

Inclusion criteria

* Early Breast Cancer patients * Postmenopausal Status * patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months

Exclusion criteria

* Advanced Breast Cancer patients(stage iii, iv) * Patients who are hard to be analysed by limitation of chart record according to investigators discretion * patients who already have been registered in this study

Design outcomes

Primary

Measure	Time frame
The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.	1 visit

Secondary

Measure	Time frame
To describe 10-year CHD risk comparing to the historical data of 10-year cancer-specific mortality in breast cancer	1 Visit
To analyse CHD management patterns according to defined 10-year CHD risk categories	1 Visit
To describe correlation between concommitant medication(Anthracycline, Trasuzumab) and CHD risk	1 Visit

Countries

South Korea

Outcome results